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ACE-                 Angiotension converting enzyme 
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DD-                   Diastolic dysfunction 
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DHF –               Diastolic heart failure 
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RAAS-            Renin angiotensin activating system 
SHF-               Systolic heart failure 
SR-                 Sarcoplasmic reticulum 
TPFR-            Time to peak filling rate 
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ABSTRACT 
BACKGROUND: Diastolic dysfunction (DD) is present in more than one third of 
patients with heart failure. Different mechanisms have been postulated for the 
pathogenesis of DD. Among them, inflammatory hypothesis is well documented. 
High sensitivity- c reactive protein (hs-CRP) is a well known biomarker of   
inflammation. Hence, we analyzed the relationship between serum hs-CRP levels 
and diastolic dysfunction in patients with cardiovascular risk factors such as 
hypertension, diabetes mellitus and dyslipidemia.   
 
METHODS: We randomly selected 100 outpatients with cardiovascular factors 
who were asymptomatic and taking medications. They were divided into six 
groups depending upon the no of risk factors they had. We measured their serum 
hs-CRP levels by immunoturbidometry, and estimated their left ventricular 
diastolic function using echocardiography. Statistical analysis was done to find the 
association between the two variables. 
 
RESULTS: Among the 100 patients: males were 56, females 44, the mean age was 
52±9, the mean BMI was 30.5±3.18, 20% were hypertensives, 20% had diabetes 
mellitus, 22% had both diabetes and hypertension,10% had hypertension and 
dysplipidemia, 14% had diabetes and dyslipidemia, and 14% had all three risk 
factors. Diastolic dysfunction was present in 62% of the patients of which 66.13% 
had Grade I diastolic dysfunction and 33.87% had Grade II diastolic dysfunction. 
Statistical analysis showed significant association between age and DD (p<0.001) 
as well as between BMI and DD (p<0.001). There was a strong relationship 
between hs-CRP levels and DD (p=0.001) 
 
CONCLUSION: Elevated hs-CRP level is independently associated with diastolic 
dysfunction in asymptomatic patients with cardiovascular risk factors. 
 
KEYWORDS: Diastolic dysfunction, hs-CRP, cardiovascular risk factors. 
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INTRODUCTION 
Heart failure is a clinical syndrome in which an abnormal cardiac function 
causes failure of the heart to pump blood that is needed to maintain the 
metabolic requirements of various tissues. This could be due to either a 
contraction or relaxation abnormality, former is called as systolic failure and the 
latter is termed diastolic failure.  
Diastolic dysfunction occurs in approximately 40-50% 
1 
of people with heart 
failure. Various mechanisms are involved in the pathogenesis of diastolic 
dysfunction. Inflammatory fibrosis is a major factor implicated in diastolic 
dysfunction.  
Traditional cardiovascular risk factors such as diabetes mellitus, hypertension 
are pro-inflammatory states that could cause myocardial stiffening and result in 
diastolic dysfunction. 
C - reactive protein (CRP) is an acute phase protein produced in the liver in 
response to inflammation in the body. It has been used to predict cardiovascular 
risk in the general population.  
Recent studies
2, 3 
have shown that there is definite correlation between diastolic 
dysfunction and hs-CRP levels in blood in patients with cardiovascular risk 
factors. 
 8 
 
Ridker et al. 2000 and Olsen et al. 2008 showed that hs-CRP could be used to 
predict cardiovascular events in the general population. 
Torwezki et al. 1998 and Zwaka et al. 2001 found that hs-CRP could play a role 
in the pathogenesis of atherosclerosis. 
deFillipi et al. 2003. and conen et al.2006 gave us some data regarding the risk 
of major adverse cardiac events in patients with cardiovascular risk factors. 
Rajaram V et al 2011 and Masugata et al. 2011 have reported a significant 
association between hs-CRP levels and diastolic dysfunction in patients with 
cardiovascular risk factors. 
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REVIEW OF LITERATURE 
Heart failure (HF) occurs when the heart is not capable to pump adequate 
amount of blood to meet the metabolic demands of various tissues. 
Historical Aspects: 
Manuscripts about heart failure can be found in the ancient medical literature in 
Egypt, Greece, and India. Foxglove was used by the Romans to treat heart 
failure. 
William Harvey explained about the circulation which helped to gain new 
insights about heart failure in 1926. The advent of x-rays and 
electrocardiography in 1890s significantly improved the investigation of heart 
failure.  Newer modalities like echocardiography, cardiac catheterization, and 
nuclear medicine have widened the diagnostic options in heart failure and 
helped in improving patient care. 
Phlebotomies and leeches were used in the very early period. William 
Withering described about the uses of digitalis in 1785. Southey’s tubes were 
used to drain the fluid from the peripheries in the 19
th
 and 20
th
 centuries. In the 
1950s thiazide diuretics were started to be used in heart failure
4
. Vasodilators 
like angiotension converting enzyme inhibitors were introduced in 1970s
5
. 
CONSENSUS-I study report published in 1987 proved without doubt the 
survival benefits of  enalapril in patients having severe heart failure
6
. 
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EPIDEMIOLOGY OF HEART FAILURE 
Heart failure has become a significant public health problem and has reached 
epidemic proportions. It is causing significant morbidity and mortality and is 
draining a major chunk of the health care expenses. 
More and more patients are presenting with diastolic heart failure for which 
definitive therapy is still lacking. Hospital admission and readmissions have 
increased over a period of time. 
PREVALENCE  
The prevalence of heart failure is around 1–2% in the US and Europe7 . 
As per American Heart Association (AHA) 2013 update, there were 5.1 million 
people with heart failure in the US in 2006 and 23 million people with heart 
failure worldwide
8
. 
Prevalence of heart failure increases with age. Framingham Heart Study showed 
a prevalence of HF in men of 8 per 1000 at age 50 to 59 years, which increased 
to 66 per 1000 at ages 80 to 89 years, same trend was noted in women. The 
prevalence in African-Americans was found to be 25 percent more than in 
whites
9
. 
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Fig1.Prevalence of Heart Failure
10
 
 
INCIDENCE: 
Incidence of heart failure is up to 5-10 per thousand per year
11
 
Nearly half a million people newly develop heart failure annually in the United 
States each year
12
.  
The incidence of heart failure is equal among men and women, and African-
Americans have 1.5 times more chance of developing heart failure than 
whites
13
. 
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One in 9 deaths in 2009 was contributed by heart failure. About 50% of people 
who develop heart failure die within 5 years of diagnosis
14
.  
Indian Scenario: 
Accurate estimates of  the incidence and prevalence of heart failure is lacking in 
India, however a conservative estimate of the prevalence of heart failure  due to 
ischemic heart disease,  obesity, diabetes, hypertension and rheumatic heart 
disease  ranges from 1.3 to 4.6 million, with an annual incidence of 0.45-1.8 
million
15
. 
Lifetime risk: 
According to Framingham Heart study, in male and female above 40, the life 
time risk of  developing heart failure is about 20%.Without preceding MI, the 
chance of developing heart failure, at age 40,was 11% for men and 16% for 
women. 
Mortality:  
Heart failure causes nearly 287,000 deaths a year. Sudden death is six to nine 
times more common in patients with CHF than the general population. Deaths 
from heart failure have decreased by approximately 12 percent per decade for 
both male and female over the past fifty years.  
 13 
 
This can be attributed to current therapies for cardiac disorders, such as 
myocardial infarction (MI), valvular heart disease, and arrhythmias, which are 
increasing the longevity
16
. 
. 
 
COMPARISON OF SURVIVAL IN SYSTOLIC AND DIASTOLIC FAILURE 
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EPIDEMIOLOGY OF DIASTOLIC HEART FAILURE (DHF) 
Data from various epidemiologic studies suggest that prevalence of diastolic 
heart failure to be around 40-50%
17
. The prevalence of diastolic dysfunction 
increases rapidly with age, this phenomenon is more prominent in female than 
in male.  
Mortality: 
The prognosis of patients with diastolic heart failure is marginally better than 
patients with systolic failure 
18
. The annual mortality rate for patients with 
diastolic heart failure approximates 5% to 8%
19
. 
Morbidity: 
Most of the studies that have compared the morbidity rates in SHF and DHF 
have reported more or less similar outcomes
20 
. The factors that were considered 
were hospital admission rates, six minute walk distance and Minnesota living 
with heart failure questionnaire. 
Morbidity from diastolic heart failure is ever increasing, causing frequent 
outpatient treatment, hospital admissions, and the expenditure of significant 
healthcare resources.  
Half of the patients with diastolic heart failure get readmitted within a year. This 
morbidity rate is similar to patients with systolic heart failure. 
 15 
 
 
Cause of death in patients with HFnlEF. 
 
 
Comparison of cause of death in diastolic and systolic failure
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HEART FAILURE: TYPES 
Heart failure can be divided into two types based on the mechanisms involved 
namely: 
 Heart failure with reduced ejection fraction (systolic heart failure) 
 Heart failure with preserved ejection fraction(diastolic heart failure) 
SYSTOLIC HEART FAILURE 
CAUSES
21
: 
Coronary artery disease 
 Myocardial infarction 
 Myocardial ischemia 
Chronic pressure overload 
 Obstructive valvular disease 
 Hypertension 
Chronic volume overload 
 Regurgitant valvular lesions 
 Left to right shunts 
 Extracardiac shunts 
Non ischemic cardiomyopathy 
 17 
 
 Familial and inherited disorders 
 Toxic and drug induced 
 Metabolic  
 Viral myocarditis 
 Chagas disease 
 
In developed countries coronary artery disease is the leading cause of systolic 
heart failure, it contributes to 60% to 75% of the cases of heart failure
22
.  
While in developing countries valvular heart disease is a major contributing 
factor. 
Hypertension, diabetes mellitus and coronary artery disease are rapidly 
emerging as significant factors causing heart failure in developing nations.  
In about 20-30% cases of heart failure the exact etiology could not be found out. 
They are referred to as non-ischemic, dilated and idiopathic cardiomyopathy. 
Many cardiomyopathies are increasingly being attributed to genetic defects 
involving the cytoskeletal proteins namely desmin, cardiac myosin,laminin and 
vinculin.  Familial cardiomyopathies are inherited in a autosomal dominant 
fashion. Muscular dystrophies like Duchene’s, Becker’s and limb girdle are 
associated with dilated cardiomyopathies. 
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PATHOGENESIS OF SYSTOLIC FAILURE 
HF may be viewed as a progressive disorder that is initiated after an index 
event either damages the cardiac muscle, with a resultant loss of 
functioning cardiac myocytes or alternatively disrupts the ability of the 
myocardium to generate force, thereby preventing the heart from 
contracting normally. 
This index event may have an abrupt onset, as in the case of myocardial 
infarction, or it may have gradual or insidious onset, as in the case of 
hemodynamic pressure or volume overload; or it may be hereditary, as in 
the case of many genetic cardiomyopathies. 
Regardless of the inciting event, the feature common to each of these 
index events is that they all in some manner produce a decline in the 
pumping capacity of  the heart. 
In majority of cases the patient remains asymptomatic for a long period of 
time after the initial decrease in pumping capacity of the heart. They 
present mostly when some acute event precipitates an acute 
decompensated heart failure
23
. 
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Pathogenesis of heart failure with a depressed ejection fraction
24
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Systolic Heart Failure: Basic Mechanisms 
LV remodeling occurs as a reaction to a series of complex events that happen at 
the cellular and molecular levels 
Overview of Left Ventricular Remodeling 
 
Alterations in Myocyte Biology 
     Excitation-contraction coupling 
     Myosin heavy chain (fetal) gene expression 
    Adrenergic desensitization 
    Hypertrophy 
    Myocytolysis 
    Cytoskeletal proteins 
Myocardial Changes  
    Myocyte loss 
    Necrosis 
    Apoptosis 
    Autophagy 
   Alterations in extracellular matrix 
     Matrix degradation 
    Myocardial fibrosis 
 21 
 
Alterations in Left Ventricular Chamber Geometry  
     Left ventricular (LV) dilation 
    Increased LV sphericity 
    LV wall thinning 
    Mitral valve incompetence 
 
 
Sustained neurohormonal activation and mechanical overload result in 
transcriptional and posttranscriptional changes in the genes and proteins that 
regulate excitation-contraction coupling and cross-bridge. 
 The changes that regulate excitation-contraction include decreased function of 
sarcoplasmic reticulum Ca
2+
 adenosine triphosphatase (SERCA2A), resulting in 
decreased calcium uptake into the sarcoplamsic reticulum (SR), and 
hyperphosphorylation of the ryanodine receptor, leading to calcium leakage 
from the SR. The changes that occur in the cross-bridges include decreased 
expression of -myosin heavy chain and increased expression of -myosin heavy 
chain, myocytolysis, and disruption of the cytoskeletal links between the 
sarcomeres and the extracellular matrix. Collectively, these changes impair the 
ability of the cardiac myocyte to contract and contribute to the depressed LV 
systolic function observed in patients with HF. Eventually leading to the 
 22 
 
progression of heart failure by virtue of the harmful effects on the heart and 
circulation. 
Changes in Cardiac myocyte in response to hemodynamic load
25
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Treatment of chronic heart failure patients with a depressed 
ejection fraction 
After the clinical diagnosis of HF is made, it is important to treat the patient's 
fluid retention before starting an ACE inhibitor (or an ARB if the patient is 
ACE-intolerant).  
Beta blockers should be started after the fluid retention has been treated and/or 
the ACE inhibitor has been uptitrated. If the patient remains symptomatic, an 
ARB, an aldosterone antagonist, or digoxin can be added as "triple therapy."  
The fixed-dose combination of hydralazine/isosorbide dinitrate should be added 
to an ACE inhibitor and a beta blocker in African-American patients with 
NYHA class II–IV HF. Device therapy should be considered in addition to 
pharmacologic therapy in appropriate patients 
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DIASTOLIC DYSFUNCTION (DD): 
Diastolic dysfunction is a term used to denote a problem in the mechanical 
properties of the ventricle such as relaxation, distensibility, and filling.  
DIASTOLIC HEART FAILURE (DHF) 
DHF indicates the signs and symptoms of clinical HF in a patient with a normal 
EF and LV diastolic dysfunction. 
Diastolic heart failure occurs when there is decrease in the performance of the 
ventricles during diastole. During diastole heart relaxes and filled with blood 
returned through superior and inferior vena cava to right atrium and through the 
pulmonary veins to the left atrium.  
Physiology of diastole: 
During diastole, the ventricular pressure drops from the peak attained at the end 
of systole. When this pressure decreases below the atrial pressure, atrio-
ventricular valves open and the blood passes from the atria into the ventricles. 
First, ventricles are filled by a pressure difference but at the end, atria contract 
and force more blood to pass into ventricles. Atrial contraction contributes to 
20% of the total filling blood volume
26
. Normal left ventricular filling is 
necessary to maintain an adequate cardiac output. Left ventricular filling is 
 25 
 
governed by ventricular relaxation and compliance, atrio-ventricular gradient, 
atrial contraction, mitral valve area and end-systolic volume.  
 
 
PHASES OF CARDIAC CYCLE 
 
Diastole has four phases: 
 Isovolumetric relaxation 
 Rapid filling phase 
 Diastasis 
 26 
 
 Atrial contraction 
 
Isovolumetric relaxation: 
It is the part of the cardiac cycle placed between aortic valve closure and mitral 
opening, during which the ventricular muscle decreases its tension without 
lengthening so that ventricular volume remains unaltered. Left ventricular 
pressure decreases below the pressure in the aortic root, which closes the aortic 
valve. When the LV Pressure becomes less than the left atrial pressure, the 
mitral valve opens, and rapid filling begins. 
Rapid filling phase: 
When left ventricular pressure becomes less than left atrial pressure the mitral 
valve opens.  Rapid filling of the left ventricles occurs which is governed by the 
atrioventricular pressure gradient and the impedance of the mitral valve 
 
Diastasis: 
Diastasis is the middle stage of diastole during which the initial passive filling 
of the ventricles has slowed down, due to decrease in the atrio-ventricular 
pressure gradient. It is represented by the H-wave in the jugular venous pulse 
tracing. 
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Atrial contraction: 
During this phase the atrium contracts and forces the blood into left ventricle.          
This phase is influenced by left atrial function. This phase is responsible for the 
production of S4. It is present in when the ventricle compliance is reduced as 
seen in ventricular hypertrophy and in old age. 
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DIASTOLIC DYSFUNCTION –PATHOPHYSIOLOGY 
Diastolic dysfunction occurs when there is change in the mechanical properties 
of the left ventricle such as myocardial relaxation and passive ventricular filling. 
It is caused by the following mechanisms.  
Slow/incomplete myocardial relaxation:  
When the left ventricle is hypertrophied, the decrease in the rate of pressure in 
the left ventricle during diastole is delayed, ultimately leading to impaired 
relaxation. This is the cause of diastolic dysfunction in left ventricular 
hypertrophy.                         
Decreased ventricular peak filling rate:  
The filling rate depends on the pressure gradient between the left ventricle and 
atrium, and the ability of the left ventricle to generate a negative pressure to 
draw blood into it. If either is affected then diastolic dysfunction can occur. 
Structural changes:  
Changes happening in the extracellular matrix causes loss of elasticity of the left 
ventricle leading to stiffness, neurohumoral mechanisms can be attributed to 
these events.  
 29 
 
Extramyocardial causes: Pericardial diseases can elevate the LV pressure and 
impair LV filling. Eventually these mechanisms will cause a steeper rise in LV 
end-diastolic pressure (LVEDP) at any given LV end-diastolic volume 
(LVEDV) than what occurs in a normal left ventricle
27 
 
 
 
(Pressure–volume curve of LV in diastole in DD, the curve clearly depicts a 
increased change in pressure for a given volume occurring in DD. ) 
 
 
 
 30 
 
 
Pathophysiology of  Diastolic Dysfunction: Algorithm
28 
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DIASTOLIC DYSFUNCTION: MECHANISMS 
Mechanisms that cause diastolic dysfunction can be divided into two types 
namely myocardial and extramyocardial. 
  Extramyocardial: 
 Hemodynamic load: early diastolic load, after load 
 Heterogeneity 
 Pericardium 
Myocardial: 
 Cardiomyocyte 
 Calcium homeostasis alteration 
 Myofilament modifications 
 Energetics 
 Cytoskeleton changes 
 Extracellular matrix 
 Neurohumoral activation           
Cardiomyocyte: 
Changes in the calcium homeostasis 
 Abnormalities in the sodium calcium exchanger and calcium pump 
causing expulsion of calcium from the cytosol. 
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 Decrease in sarcoplasmic reticulum(SR)  calcium ATPase  causing 
problems in SR ca2+ . 
 Changes in phospholamban, calmodulin, and calsequestrin which modify 
SR Ca2+ ATPase. 
These above changes increase the cytosolic calcium concentration during 
diastole and slow down the decline of calcium in diastole, resulting in abnormal 
relaxation and passive stiffness
29
. 
Myofilaments: 
Myofilament consists of thick-filament myosin and thin-filament actin proteins. 
Regulatory proteins such as tropomyosin, troponin(Tn), T,C and I are bound to 
actin. ATP hydrolysis is needed for myosin separation from actin during 
relaxation and also for calcium detachment from Tn-C, and sequestration of 
calcium in SR. 
For normal diastolic function the products of ATP hydrolysis such as ADP and 
Pi should be less than ATP, if  the ratio is altered then diastolic dysfunction 
occurs
30
. 
Cardiomyocte cytoskeleton contains microtubules, desmin, actin, titin, nebulin, 
alpha-actinin, myomesin. Cytoskeletal alterations have shown to cause diastolic 
dysfunction. Especially titin isotypes modifications have been reported to cause 
impaired relaxation and viscoelastic stiffness
31
. 
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Myofilament Modifications: Abnormalities of calcium reuptake proteins 
Extracellular matrix: 
Myocardial ECM contains  
 Fibrillar proteins: collagen type I-III and elastin  
 proteoglycans 
 basement proteins-, laminin, collagen type IV and fibronectin.  
 Disease processes that causes diastolic dysfunction cause alterations in 
the amount, distribution, geometry, degree of crosslinking, ratio of typeI 
to typeII collagen
32
. 
Treatments that normalize diastolic function also correct the above mentioned 
changes. 
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Neurohumoral and cardiac endothelial activation: 
Neurohumoral activation on the long run can cause diastolic dysfunction. 
Chronic activation of RAAS increases the ECM fibrillar collagen and causes 
stiffness. Inhibition of RAAS decreases the fibrillar collagen and eases the 
myocardial stiffness
33
. Not only chronic but also acute activation or inhibition 
of  the neurohumoral  and  cardiac endothelial units can alter the diastolic 
properties of the left ventricle. 
Treatment with ACE inhibitor and direct NO donor decreases the left 
ventricular pressure and shifts the pressure vs volume curve to the right 
ultimately decreasing the stiffness.  
There is a periodic release of nitric oxide mainly subendocardially which 
happens at the moment of relaxation and filling. This also plays an important 
factor in the duration of diastolic relaxation. Newer drug like the indirect 
endothelin-dependent nitric oxide donors target this pathway.  
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Activation of neurohormonal systems in heart failure 
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AETIOLOGY OF DIASTOLIC DYSFUNCTION 
Diastolic Dysfunction: Causes 
Common causes: 
 Cardiac ischemia 
 Hypertension 
 Aging 
 Obesity  
 Aortic stenosis 
 Diabetes mellitus 
 Renal dysfunction 
 Obstructive sleep apnea 
Rare causes: 
 Hypertrophic cardiomyopathy 
 Amyloidosis 
 Sarcoidosis 
 Hypereosinophilic syndrome 
 Glycogen storage diseases 
 Hemochromatosis 
 Constrictive pericarditis 
 37 
 
 Pericardial effusion 
Aging:  
Diastolic dysfunction steadily declines with age, even in the absence of 
cardiovascular diseases.  
Structural cardiac changes with aging such as increased cardiomyocyte size, 
increased apoptosis, and focal collagen deposition may contribute to diastolic 
dysfunction with normal aging
34
  
Gender: 
Female sex is prone for developing DHF. Prevalence of diastolic dysfunction 
increases as age increases in women for not clearly attributable reasons. 
Vascular and LV systolic and diastolic stiffness is more in women than men, 
and these factors increase more steeply in females
35
. 
 Obesity: 
Obesity is more common in DHF than systolic failure. Obese persons are more 
prone to develop diastolic dysfunction
36
.  
Enhanced adiposity is a source of many biologically active peptide and 
nonpeptide mediators which in turn lead to chronic inflammation. Increased 
 38 
 
BMI is a breeding ground for cardiovascular risk factors such as hypertension, 
diabetes mellitus, which in turn lead to diastolic dysfunction. 
 Hypertension: 
Hypertension is the most common risk factor for development of DHF. 
Long standing hypertension causes left ventricular remodeling and functional 
changes. Hypertension leads to LVH, augments ventricular stiffness, reduces  
relaxation eventually predisposing to the development of diastolic 
dysfunction
37
. 
Diabetes mellitus: 
Diabetes mellitus is a common risk factor for development of heart failure and it 
can cause both systolic and diastolic heart failure. 
 The structural changes in the diabetic heart include myocyte hypertrophy, 
increased extracellular matrix (fibrosis), and intramyocardial microangiopathy. 
Functional changes impaired endothelium vasodilation, impaired LV relaxation, 
increased passive diastolic stiffness, and contractile dysfunction
38
.Increase in 
advanced glycation end products, which promote increased collagen 
accumulation and increased collagen stiffness. Accumulation of advanced 
glycation end products may play a role in age-related cardiac and vascular 
stiffening. 
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Coronary Artery Disease 
Prevalence of ischemic heart disease in patients with DHF varies widely. 
Ischemic cardiomyopathy decreases the chamber compliance and impairs 
relaxation, thereby causing diastolic dysfunction
39
. 
Renal Dysfunction 
Effect of renal dysfunction on the outcome of patients with heart failure is well 
documented
40
. Acute decompensated heart failure due to diastolic dysfunction 
can occur due to flash pulmonary edema in patients with bilateral renal artery 
stenosis. In a patient presenting with the triad of hypertension, renal 
dysfunction, and diastolic, renal Doppler should be done. 
Rarer Causes of DHF: 
Hypertrophic obstructive cardiomyopathy, amyloidosis, and constrictive 
pericarditis are possibilities to be considered in differential diagnosis in a 
younger individual with symptoms suggestive of diastolic heart failure. 
Idiopathic restrictive cardiomyopathy in young person usually has positive 
family history. Radiation can cause damage to both pericardium and 
myocardium and lead to persistent HF. 
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Clinical Features of Diastolic Heart Failure  
There is no big difference between the signs and symptoms of diastolic and 
systolic failures only the percentages differ.  Mostly diastolic dysfunction is 
asymptomatic. In majority of cases the first noticed symptom is exercise 
intolerance, followed by paroxysmal nocturnal dyspnoea, and orthopnoea
41
.  
                           Comparison of signs and symptoms in SHF and DHF 
Symptoms DHF SHF 
Exertional dyspnea 85% 96% 
Paroxysmal nocturnal dyspnea 55% 50% 
Orthopnea 60% 73% 
Physical examination  
Jugular venous distension 35% 46% 
Displaced apical impulse 50% 60% 
S3 45% 45% 
S4 45% 66% 
Hepatomegaly 15% 16% 
Oedema 30% 40% 
Cardiomegaly 90% 96% 
Pulmonary venous hypertension 75% 96% 
 
Only paroxysmal nocturnal dyspnea is relatively more common in DHF than 
SHF. All other signs and symptoms are more common in SHF. 
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DIAGNOSTIC CRITERIA FOR DIASTOLIC HEART FAILURE 
 
Definitive DHF Probable DHF Possible DHF 
Definitive evidence of 
Congestive  cardiac 
failure 
Same as definitive  Same as definitive 
and and  And 
Objective evidence of 
normal systolic function  
Same as definitive LV EF of 50%  or more 
not measured within 72 
hrs of the event  
and and And 
Objective evidence of 
diastolic dysfunction 
No conclusive evidence 
of DD 
Same as probable 
 
Patients who have definitive evidence of congestive cardiac failure and 
objective evidence of normal LV systolic function are accepted as having 
probable diastolic heart failure provided valvular and other non-cardiac causes 
have been excluded. 
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ASSESSMENT OF DIASTOLIC FUNCTION  
The study of LV diastolic properties requires simultaneous measurement of 
pressure and volume. Both invasive and non-invasive methods can be used. 
Invasive methods using  high-fidelity micromanometer provides the most 
comprehensive evaluation. But for practical feasibility non-invasive methods 
such as Doppler echocardiography are used. 
Changes in both afterload and diastolic load can affect measurements of 
diastolic function. These load-dependent changes do not reflect alteration in 
intrinsic relaxation properties.   
Rate of  isovolumic relaxation: The rate of LV pressure decline, or the rate of 
isovolumic relaxation, reflects early diastolic function. Accurate assessment 
requires a high-fidelity micromanometer catheter. Measures of this property 
include: 
 Peak  dP/dt: Peak negative dP/dt is the peak instantaneous rate of LV 
pressure decline. 
 Tau (τ): Tau is the time constant of isovolumic LV pressure decay42. Tau 
is the slope formed when log value of left ventricular diastolic pressure is 
plotted against time. Tau is the time taken for the left ventricular pressure 
to reduce by more than 66%. 
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 Isovolumic relaxation time (IVRT): IVRT can be measured with 
noninvasive echocardiographic techniques. Isovolumic relaxation time 
(IVRT) is an interval between the aortic valve closure  to opening of the 
mitral valve. It can be used as an indicator of diastolic dysfunction. 
Normal IVRT is 70 ± 12ms. In abnormal relaxation, IVRT exceeds 110 
ms
43
. 
 
 
 
When the relaxation rate is decreased (ie, abnormal diastolic function), Tau is 
increased and the absolute value of the peak negative dP/dt is reduced. IVRT 
increases with impaired relaxation but then decreases with progressive 
worsening of diastolic function
44
.  
 44 
 
Rate and extent of LV filling: The normal LV has a characteristic pattern of 
filling and transmitral inflow velocities. A number of measures characterize the 
rate of LV filling, including: 
 LV filling rate 
 The time-to-peak-filling rate (TPFR) Transmitral flow velocity 
 Diastolic suction (flow propagation velocity) 
 Pulmonary venous flow velocities 
 Myocardial tissue velocity, strain, and strain rate. 
There are four patterns of diastolic function that can be identified using 
transmitral Doppler spectral recordings, color Doppler M-mode inflow 
propagation velocities, pulmonary vein Doppler flow measurements, and tissue 
Doppler echocardiography namely: normal, impaired relaxation, pseudonormal, 
and restrictive
45
. 
Echocardiography: Echocardiography gives useful information about 
chamber size, valve morphology, and systolic function. 2D echocardiography is 
helpful in assessing the diastolic phase of cardiac cycle.  
Transmitral flow velocity: E-wave denotes the early diastolic peak filling 
velocity and A-wave the late diastolic peak filling velocity. Former depends on 
the transmitral pressure gradient and latter on the atrial contraction. 
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E-wave is normal taller than the A-wave and hence the ratio is >1. There 
reversal of this ratio occurs in the initially stages of diastolic dysfunction. 
Progression of the diastolic dysfunction causes more reduction in compliance 
and increases the left atrial pressure, this causes the ratio to normalize. This is 
called pseudonormalization. This is the drawback of using E/A ratio, but this 
can be neutralized by using Valsalva maneuver or GTN administration during 
the procedure. 
Pulmonary venous flow: Normally there is a forward flow of blood from left 
atrium to left ventricle during atrial relaxation and left ventricular diastole, and 
there is minimal back flow during atrial contraction. In diastolic dysfunction 
this back flow of blood into the pulmonary veins becomes exaggerated. 
Isovolumetric relaxation time(IVRT): IVRT extends from aortic valve 
closure to mitral valve opening. Normal IVRT is 70±12ms. It is a good 
indicator of diastolic function. In diastolic dysfunction the IVRT becomes more 
than 110ms.  
Deceleration time (DT): It is the time taken for the fall in transmitral pressure 
gradient. Normal value is 180-240ms. In the initial stages of diastolic 
dysfunction the DT is prolonged, but it becomes shortened due to the hike in 
left atrial pressure in later stages. 
 46 
 
Tissue Doppler: Tissue Doppler helps to calculate the velocity of myocardial 
tissue movement using the Doppler shift of ultrasound waves. Following 
velocities can be calculated namely: 
E´ wave:  Peak early diastolic mitral annular velocity 
A´ wave: Late diastolic mitral annular velocity.  
 LV long-axis lengthening velocity during diastole parallels patterns found in 
transmitral diastolic inflow. In the normal heart, the rate of lengthening is 
greatest early in diastole immediately after mitral valve opening, as reflected by 
a tall E´. Lengthening resulting from atrial contraction at the end of diastole is 
relatively small reflected by a relatively small A´. 
 
GRADES OF DIASTOLIC DYSFUNCTION 
 Grade I diastolic dysfunction (impaired relaxation): When diastolic 
dysfunction initially occurs, relaxation is slowed and incomplete as 
reflected by an increased isovolumic relaxation time. This results in an 
increase in early LV diastolic pressures, a decrease in the early 
transmitral pressure gradient, and a decrease in diastolic suction as 
reflected by a decrease in color M mode flow acceleration. LV filling is 
abnormal with decreased early filling rate and extent, prolonged TPFR, 
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increased filling rate from atrial contraction, and thus, a decreased E/A 
ratio (A dominant pattern). Tissue Doppler myocardial lengthening 
velocity patterns are similar to the transmitral flow velocities, with E’ 
reduced and A’ increased.  
 
 Grade II diastolic dysfunction (pseudonormal): As diastolic dysfunction 
progresses, LV filling becomes increasingly dependent upon an increase 
in LA pressure to push blood into the LV during diastole .As LA 
pressures rise, the early diastolic transmitral pressure gradient increases, 
early diastolic flow velocities also rise and the E wave increases, causing 
the E/A ratio to increase to a ―normal‖ (or pseudonormal) value.  
However, myocardial velocity by tissue Doppler echocardiography is less 
sensitive to alteration in LV loading conditions than transmitral Doppler 
velocities and E’ (the rate of early diastolic myocardial lengthening) 
remains markedly reduced. 
 Thus, varying combinations of alterations in E and E´ help to distinguish 
impaired relaxation and pseudonormal patterns from a normal pattern. 
Impaired relaxation has low E/E´ ratio, where as in pseudonormal pattern 
the ratio can be normal or increased because E´ is very much reduced
46
.  
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 Grades III and IV diastolic dysfunction (restrictive): If left atrial pressures 
are severely increased, a "restrictive" pattern may develop in which the 
isovolumic relaxation time may be decreased, transmitral pressure gradient is 
further increased and the E/A and E/E’ ratios are markedly increased to 
supernormal levels. This restrictive pattern is characteristic of marked 
elevations in filling pressure with grade III (reversible restrictive pattern) or 
grade IV (irreversible restrictive pattern) diastolic dysfunction 
47
.  
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TREATMENT OF DIASTOLIC HEART FAILURE 
Treatment has got two objectives. First to immediately relieve the symptoms 
and to eliminate the precipitating factors. Next to reverse the factor responsible 
for the diastolic dysfunction. Both nonpharmacologic and pharmacologic 
therapy can be used to achieve these objectives. 
Symptomatic  Therapy 
                  Reduce pulmonary venous pressure 
           Improve exercise tolerance
48
 
              inotropic agents         
Non-pharmacological Therapy 
                    Salt and fluid restriction 
                    Aerobic exercise 
 
Pharmacological Therapy 
Diuretics, including loop diuretics, thiazides, spironolactone 
 Long-acting nitrates 
β-Adrenergic blockers 
Calcium channel blockers
49
 
Renin-angiotensin-aldosterone antagonists, including ACE 
inhibitors, angiotensin II receptor blockers, and aldosterone 
antagonists 
Treatment of underlying conditions 
                    Preventing myocardial ischemia 
       control of  hypertension, diabetes 
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GENERAL APPROACH 
Primary prevention includes quitting of smoking and optimal control of high 
blood pressure, diabetes mellitus, dyslipidemia, and ischemic heart disease. 
Apart from quitting smoking, other life style modifications such as weight 
reduction, dietary changes, controlling alcohol consumption, and aerobic 
exercise help to prevent not only systolic failure but also diastolic failure. 
Diastolic dysfunction remains asymptomatic for many years. Hence, early 
diagnosis and treatment is critical to prevent irreversible morphological 
alterations.  
There is no specific drug till date for the management of diastolic heart failure. 
There are well defined therapeutic options available for systolic failure but for 
diastolic failure treatment is mainly empirical.  
The treatment of diastolic heart failure is limited by the lack of data from 
definite well defined studies. 
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Heart Failure: Treatment Goals 
 
 Underlying disease Treatment 
 
Prevent and treat hypertension, diabetes mellitus and ischemic heart  
disease. 
           
          Surgically remove diseased pericardium 
 
left ventricular relaxation improvement 
 
 Calcium channel blockers 
 
          ACE inhibitors 
 
Regress left ventricular hypertrophy 
           Beta blockers 
  
 ACE inhibitors and ARBs  
 
          Aldosterone antagonists 
 
          Calcium channel blockers 
Management of arrhythmias 
         Beta blockers  
 
         Calcium channel blockers  
 
         Digoxin
50
  
 
        Atrioventricular node ablation  
Reducing mortality 
         ACE inhibitors 
 
         Beta blocker  
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Differences in the treatment of Systolic and diastolic heart failure 
The drugs being used in the treatment of DHT are more or less same as those 
used in the SHF treatment. But the internal mechanism that the drug alters are 
different as well as the dosages required. 
For example, beta-blockers decrease the heart rate and help to increase the 
duration of diastole in DHF, while in SHF on a long term basis increase the 
inotropic activity and alter the LV remodeling. In the case of SHF the titration 
of  beta-blockers must be done gradually unlike in DHF. 
Diuretics are useful in both SHF and DHF. But smaller doses are sufficient in 
case of DHF. 
Calcium channel blockers have no role in the treatment of SHF, but in DHF 
they improve left ventricular relaxation and regress the LVH. 
 Future perspectives: 
Ideally the therapeutic agent must block the underlying mechanisms causing the 
diastolic dysfunction. For example it must improve the calcium homeostasis and 
energetic, and should stop and decrease the amount of fibrosis. Unfortunately 
no such drugs are available at the moment. 
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C-REACTIVE PROTEIN 
C-reactive protein (CRP) is a protein produced in the liver
51
 in response to 
inflammation occurring anywhere in the body. It is better known as an acute-
phase reactant. Its binds to phosphocholine expressed on the surface of dead or 
dying cells resulting in the activation of the complement system through the 
C1Q complex
52
. 
CRP is synthesized in response to factors released by macrophages and 
adipocytes. It belongs to the pentraxin family of proteins
53
. It was the first   
pattern recognition receptor (PRR) to be identified
54
. 
 
 
Structure of C - reactive protein 
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CRP was first identified in the serum of patients with acute inflammation as a 
substance that reacted with the C-polysaccharide antigen of Pneumococcus. It 
was discovered by Tillett and Francis in 1930
55
. The CRP gene is located on 
chromosome one (1q21-q23). 
Biological Role: 
Acute phase response occurs in wide variety of conditions like infections, 
inflammatory states and malignancies. These conditions cause increase in 
interleukin-6 and other cytokines in the body, which in turn cause the liver to 
produce c-reactive protein. 
CRP levels start to increase within two hours of acute inflammation, reaching 
its maximum level within 48 hrs, when the inflammation subsides it returns to 
baseline within 18 hrs. 
CRP binds to phosphocholine on microbes and necrotic cells and facilitates 
phagocytosis by macrophages. In this way CRP helps in the clearance of 
necrotic and apoptotic cells. 
CLINICAL SIGNIFICANCE 
CRP is a very valuable biomarker of inflammation. 
CRP levels can be estimated by many analytical methods namely ELISA, laser 
nephelometry, immunoturbidimetry, rapid immunodiffusion, and visual 
agglutination. 
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The reference range for C-reactive protein is 0-10mg/dl 
49
. 
Conditions associated with high CRP levels (>10 mg/L) are                    
Inflammation – autoimmune disorders, rheumatoid arthritis, vasculitis 
Infection -bacterial sepsis or fungal infection 
Acute coronary syndromes 
 
CRP ranges in different conditions
56
: 
Conditions CRP Values 
Mild inflammation and viral infections  (10–40 mg/L) 
Active inflammation, bacterial 
infection, 
(40–200 mg/L) 
Severe bacterial infections and burns  (>200 mg/L) 
 
CRP AND CARDIOVASCULAR DISEASE 
High-sensitivity CRP assays measure very low levels of CRP in the blood. The 
two popular methods are laser nephelometry and immunoturbidometry. These 
assays can measure CRP to the level upto 0.04 mg/L. 
Hs-CRP plays a major role in the cardiovascular risk stratification. 
The American Heart Association has defined risk groups as  
Low Risk: < 1.0 mg/L 
Average risk: 1.0 - 3.0 mg/L 
High risk: > 3.0 mg/L 
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Ridker et al. 2000 and Olsen et al. 2008 showed that hs-CRP could be used to 
predict cardiovascular events in the general population. 
Torwezki et al. 1998 and Zwaka et al. 2001 found that hs-CRP could play a role 
in the pathogenesis of atherosclerosis. 
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AIMS AND OBJECTIVES 
 
Primary Objective: To screen for the presence of diastolic dysfunction in 
patients with cardiovascular risk factors, and to measure their serum hs-CRP 
levels. 
 
Secondary Objective: To study the association between the hs-CRP levels and 
diastolic dysfunction in the patients with cardiovascular risk factors. 
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MATERIALS AND METHODS 
SOURCE OF DATA: Data was collected from out patients with 
cardiovascular risk factors attending Rajiv Gandhi Government General 
Hospital. 
STUDY DESIGN: Cross-sectional study 
SAMPLE SIZE:  100 patients. 
Duration: 6 months (June 2013-Nov 2013) 
METHOD OF COLLECTION OF DATA: 
 
After obtaining informed consent the patients were subjected to detailed history, 
clinical examination and investigations as per the proforma. Institutional Ethics 
Committee clearance was obtained. The following criteria were applied for 
selection of patients in the study group. 
Inclusion Criteria :  
Known cases of  
 Hypertension,  
 Type 2 diabetes mellitus, 
 Dyslipidemia  
 who are under medications.  
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Exclusion Criteria: 
Patients with  
 History or clinical evidence of heart failure,  
 History of cardiovascular disease such as coronary artery disease, 
valvular heart disease, arrhythmias, stroke, peripheral vascular disease), 
 Newly diagnosed diabetes mellitus and hypertension(<1year) 
 Renal failure with serum creatinine > 1.6 
 Chronic alcoholism 
 History or clinical evidence of  recent or acute systemic 
infection/inflammation. 
METHODOLOGY: 
After obtaining informed consent from the enrolled patients, a questionnaire 
was prepared to obtain details of the patients name, age, sex occupation and 
symptoms if any. History suggestive of heart failure was given due importance. 
Vital parameters of the patients were recorded. Height and weight of the 
patients were measured to calculate the Body mass Index (BMI). The body 
mass index was calculated using the formula Body mass index = weight of the 
patient (kg) / (height)
2
 (height in metres). Routine clinical examination was 
done.
          
 
All the patients were subjected to the following investigations 
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 Blood urea nitrogen  
 Serum creatinine 
 Fasting blood sugar 
 Fasting lipid profile. 
 Complete hemogram  
 Plasma hs-CRP  
 ECG 
 Echocardiography 
For the measurement of hs-CRP 5ml of venous blood was collected in a red top 
vacutainer tube and analysed in Cobas Integra 400 analyser by using 
immunoturbidometric method. 
ASSESSMENT OF DIASTOLIC DYSFUNCTION: 
All patients enrolled in the study were subjected to echocardiography. 
Transthoracic echocardiography was done after clinical evaluation. 
Echocardiography was done using Philips HD 7 echocardiography machine and 
systolic and diastolic functions were analyzed.  
2D echocardiography was done to assess the ventricular dimensions, presence 
of regional wall motion abnormalities and left ventricular ejection fraction. The 
parasternal and long axis view were used. Ejection fraction was calculated using  
Simpson’s approach. 
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Doppler echocardiography was done and using the apical four chamber view, 
the transmitral flow velocities were obtained by positioning the sample volume 
at the level of the tips of the mitral leaflets. The early mitral inflow velocity (E) 
and late inflow velocity (A) were obtained, and E/A ratio was calculated.  
E/A ratio of less than 1 was considered as grade I diastolic dysfunction. When 
E/A ratio was more than 1, additional parameters like the velocity propagation, 
E wave deceleration time were considered to differentiate grade II diastolic 
dysfunction from normal pattern. The velocity propagation of the early mitral 
inflow was assessed using a color M mode echocardiography. 
Data obtained by the above methods were analyzed using IBM SPSS 20 
software package. 
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OBSERVATION & ANALYSIS 
PATIENT CHARACTERISTICS: 
Table 1. Sex Distribution: 
Among the 100 patients enrolled in the study, 56 were male and 44 were female 
patients. 
Table1: Sex distribution: 
Sex No. of patients(n=60) Percentage 
Males 56 56% 
Females 44 44% 
 
 
56%
44%
sex distribution
Males
Females
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Table 2. Age distribution: 
Out of the 100 patient in the study the youngest patient was 30 years old and 
oldest patient was 75 years old. The no of patients were maximum in the 51-60 
age group. The mean age of the patients was 52.92 with a standard deviation of 
10.54 
Age distribution No of patients(n=100) Percentage 
30-40 yrs 12 12% 
41-50yrs 31 31% 
51-60yrs 40 40% 
>60yrs 17 17% 
 
 
 
12%
31%
40%
17%
0%
5%
10%
15%
20%
25%
30%
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40%
45%
30-40 yrs 41-50 yrs 51-60 yrs >60 yrs
Age Distribution
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Table 3. Distribution of Cardiovascular risk factors: 
100 patients enrolled in the study were divided into six group depending upon 
the presence of cardiovascular risk factors, maximum no of patients were in C-
group which included patients with HT AND DM.  
 Distribution of cardiovascular risk factors. 
 
Group Risk Factors No. of patients(n=100) percentage 
A HT 20 20% 
B DM 20 20% 
C HT+DM 22 22% 
D HT+DL 10 10% 
E DM+DL 14 14% 
G HT+DM+DL 14 14% 
  
   
20% 20%
22%
10%
14% 14%
0%
5%
10%
15%
20%
25%
A B C D E G
CARDIOVASCULAR RISK FACTOR GROUPS 
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Table  4. PREVALENCE OF DIASTOLIC DYSFUNCTION 
Among the 100 patients in the study 62 had echocardiographic evidence of 
diastolic dysfunction. 41patients had Grade I DD and 21 patients had Grade II 
DD. 
There was no Grade III or Grade IV DD observed. All patients had EF>50%. 
None of the patients had clinical evidence of heart failure. 
 
 
 
 
DD-GRADE 
NO OF 
PATIENTS(n=62) 
 
PERCENTAGE 
DD I 41 66.13% 
DD II 21 33.87% 
 
38%
62%
DD-PERCENTAGE
NORMAL
DIASTOLIC DYSFUNCTION
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Table  5. AGE AND DIASTOLIC DYSFUNCTION: 
 
The prevalence of diastolic dysfunction increases with age. In our study highest 
percentage of diastolic dysfunction was observed in above 60 age group. 30-40 
age group had the lowest percentage. 
 
AGE GROUP(n=100) No of patients with 
diastolic dysfunction(n=62) 
 
PERCENTAGE 
Grade I Grade II 
30-40years(n=12) 2 0 16.67% 
41-50years(n=31) 10 0 32.26% 
51-60 years(n=40) 25 9 85.00% 
Above 60(n=17) 4 12 94.12% 
 
 
By Pearson Chi square test, for the above values p value < 0.001** significant 
at 1% level. Correlation co-efficient between age and hs-CRP was r = 0.593, 
which is positive correlation. 
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Table  6. SEX AND DIASTOLIC DYSFUNCTION: 
Out of the 56 males 34 patients had diastolic dysfunction and in females 
patients 28 had diastolic dysfunction. Percentage was slightly higher in the 
female patients. 
 
SEX(n=100) 
No of patients with 
diastolic dysfunction(n=62) 
 
    PERCENTAGE 
Grade I Grade II 
Male(n=56) 21 13 60.71% 
Female(n=44) 20 8 63.63% 
 
 
By Pearson Chi square test, for the above values p value = 0.693, statistically 
not significant.  
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DISTRIBUTION OF DD-GRADES IN BOTH SEXES 
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Table  7. DISTRIBUTION OF DIASTOLIC DYSFUNCTION AMONG 
VARIOUS RISK FACTORS GROUPS 
 
Patients were divided into six risk groups. 
 
 
Group 
 
 
Risk Factors 
No of patients with diastolic 
dysfunction(n=62) 
 
PERCENTAGE 
Grade I Grade II 
A(n=20) HT 10 3 65% 
B(n=20) 
 
DM 10 3 65% 
C(n=22) 
 
HT+DM 8 6 63.64% 
D(n=10) 
 
HT+DL 4 1 50% 
E(n=14) 
 
DM+DL 4 1 35.71% 
G(n=14) 
 
HT+DM+DL 5 7 85.71% 
 
 By Pearson Chi square test, for the above values p value = 0.125, statistically 
not significant.
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Grades of DD in various Risk Factor Groups 
 
 
 
 
 
 
 
 Patients who had hypertension, diabetes mellitus and dysplipidemia had highest 
percentage of DD. Patients with diabetes and dyslipidemia had the least  
 
Percentage of DD. In patients who had only hypertension or diabetes the 
prevalence of DD was equal. 
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Table 8. Body Mass Index and Diastolic Dysfunction: 
 
BMI was calculated for all the patients using the formula BMI = W/H
2 
were W 
is the weight is kilograms and H is the height in metres.  
The mean was 30.68 and the standard deviation was 2.98. 
The minimum value was 23.4 and the maximum value was 36.4 
 
 
 
    BMI (n=100) 
No of patients with 
diastolic dysfunction 
(n=62) 
   
   
     Percentages 
Grade I Grade II 
        <25 (n=4) 1 0 25.00% 
   25-29.9(n=43) 16 2 41.86% 
      ≥30(n=53) 24 19 81.13% 
 
  
By Pearson Chi square test, for the above values p value < 0.001** significant 
at 1% level. 
 
Correlation co-efficient between BMI and hs-CRP was r = 0.538, which is 
positive correlation. 
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BMI AND DIASTOLIC DYSFUNCTION 
X-axis – BMI 
Y-axis – DD  
According to our study there was statistically significant association between 
the BMI and DD 
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Table 9. hs-CRP and Diastolic Dysfunction: 
hs-CRP levels were measured for all the patients in the study. The least value 
recorded was 0.11 mg/dl and the maximum value was 2.36 mg/dl.  
The mean value was 0.70 with a standard deviation of 0.52. 
hs-CRP values above 0.5mg/dl had significant association with diastolic 
dysfunction. 53% of patients with DD had values more than 0.5mg/dl 
 
 
hs-CRP value(n=100) 
mg/dl 
 
Diastolic dysfunction   
  
    PERCENTAGES 
 
Grade I 
(n=41) 
 
Grade II 
(n=21) 
<0.5(n=47) 10 1 23.40% 
0.5-1.0(n=32) 23 8 96.86% 
>1.1(n=21) 8 12 95.24% 
 
 
  
By Pearson Chi square test, for the above values p value = 0.001** significant 
at 1% level. 
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hs-CRP and Diastolic dysfunction 
X-axis: hs-CRP 
Y-axis: Diastolic dysfunction 
According to our study there was statistically significant association between 
the hs-CRP and DD 
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DISCUSSION 
Diastolic dysfunction and age:  
High statistical significance (P < 0.001**) was observed for the association 
between age and diastolic dysfunction. 
According to our study increasing age is a risk factor for development of 
diastolic dysfunction. Above the age of 50 nearly 89% of the patients had 
diastolic dysfunction. From this it is quite clear that age and diastolic 
dysfunction have a linear relationship. 
Fischer et al. (2002), have reported the prevalence of  diastolic dysfunction is 
more common than systolic dysfunction as the age advances and in the presence 
of  risk factors. 
According to Kuznetsova et al. (2009) the prevalence of diastolic dysfunction in 
general population was as high as 27.3%. The mean age of the patients in the 
study was 52.7 years. 
Arbab-Zadeh et al. 2004 have shown that left ventricular diastolic stiffness is 
increased in sedentary elderly people when compared to person with active life 
style and sustained endurance training can preserve the left ventricular 
compliance with aging. 
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Diastolic dysfunction and sex: 
In our study the prevalence of diastolic dysfunction was slightly higher in 
females than in males but no underlying causes or mechanisms could be 
attributed to this difference. 
Mohamed et al. (2004) showed that in patients with systemic hypertension the 
development of development of diastolic dysfunction did not have any 
particular gender preference. 
R. Wachter et al. (2007) showed that the presence of diabetes has an influence 
on the diastolic function in males but there was no difference in females 
between the diabetic and non-diabetic population.  
Wong et al. (1989) and Ghali et al. (1991) have reported that female gender as a 
good predictor of development of diastolic dysfunction. 
Whereas other studies such as Warnowicz et al. (1983), Dougherty et al (1984), 
Kinney et al (1989), Cocchi et al (1991)., have not included gender as a positive 
predictive factor for development of diastolic heart failure. 
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 Diastolic Dysfunction and BMI 
 High statistical significance (P < 0.001**) was observed for the association 
between BMI and diastolic dysfunction.  
53% of the patients had BMI more than 30, out of which 83% had diastolic 
dysfunction. However, these patients had different associated risk factors. 
Hence obesity alone cannot be fully attributed to the development of diastolic 
dysfunction. 
Recent study Russo C et al. (2011) has shown that increased BMI was 
associated with poor left ventricular diastolic function which is independent of 
left ventricular hypertrophy and other associated risk factors.  
Persic V et al. (2007) found out that obesity in newly diagnosed hypertensives 
contributed to the development of diastolic dysfunction. 
A large recent Japanese study (n=692) Kinuko Dote et al. (2011) had found a 
good correlation between obesity and presence of diastolic dysfunction. The 
mean and  standard deviation of the BMI in obese patients was 33.1±3.6kg/m2  
with a range of 30.0–44.7 kg/m2. 91% of the obese patients had diastolic 
dysfunction when compared to 77% in the normal weight category. 
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Diastolic Dysfunction and Risk factor group: 
The patients were divided into six risk factor groups. Highest percentage of 
diastolic dysfunction was observed in patients who had hypertension, diabetes 
mellitus as well as dyslipidemia.  
There was no significant difference in the prevalence of diastolic dysfunction 
between patients who had only hypertension and those who had only diabetes.  
There was not much statistically significant association between the risk factor 
groups and diastolic dysfunction. 
Khalil S J et al. (2007) estimated that about 58% of the diabetic patients had 
diastolic dysfunction of which majority of them had Grade I diastolic 
dysfunction. Cosson et al. (2007) demonstrated that 69% of the diabetics have 
abnormalities in diastolic filling. 
A Nigerian study SO Ikeh et al. (2006) reported the prevalence of diastolic 
dysfunction in hypertensive patients as high as 82.86% where as in 
normotensive controls it was 34.29%. 
Verdecchia P et al. (1990) reported a prevalence of  46-48% of diastolic 
dysfunction in hypertensive patients in European population.  
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hs- CRP and Diastolic dysfunction: 
High statistical significance (P < 0.001**) was observed for the association 
between hs-CRP and diastolic dysfunction. 
Out of the patients with diastolic function (n=62) 91% showed a definite 
positive association between their serum hs-CRP levels and degree of diastolic 
dysfunction.  
Rajaram V et al (2011) in a study that included the assessment of diastolic 
dysfunction in African Americans with cardiovascular risk factors found out a 
significant association between diastolic dysfunction and hs-CRP levels. 
Masugata et al. (2011) a Japanese study which assessed the association between 
hs-CRP levels and Doppler echocardiographic parameters of diastolic 
dysfunction in patients with cardiovascular risk factors also reported definite 
correlation. 
Hence based on our study and recent studies as quoted we suggest that serum 
hs-CRP can be used as a marker for diastolic dysfunction in patient with 
cardiovascular risk factors.  
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CONCLUSION 
According to our study conducted on 100 patients with cardiovascular risk 
factors without clinical evidence of heart failure and normal systolic function. 
 Diastolic dysfunction is common in patients with cardiovascular risk 
factors such as hypertension, diabetes mellitus and dyslipidemia. Grade I 
diastolic dysfunction is more commonly encountered. Grade III and 
Grade IV diastolic dysfunction were not encountered. Hence 
echocardiographic evaluation is needed in all patients with cardiovascular 
risk factors. 
 Increasing age in patients with cardiovascular risk factors is associated 
with increased prevalence of diastolic dysfunction. Especially above 50 
years. 
 Female sex has a marginally higher prevalence of diastolic dysfunction 
when compared to males. 
 Obesity has a very strong correlation with diastolic dysfunction.  
 More the number of cardiovascular risk factors in a patient more are the 
chances of developing diastolic dysfunction. 
 hs- CRP levels have a significant association with diastolic dysfunction in 
patients with cardiovascular risk factors. This relationship is independent 
of all other risk factors.  
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 Therefore hs-CRP can be used as a marker for diastolic dysfunction in 
patients with cardiovascular risk factors, who are asymptomatic. 
 Treatment strategies targeted at the underlying pathogenic mechanisms 
could potentially reverse the diastolic dysfunction and thereby reduce 
cardiovascular mortality. 
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 PROFORMA 
 
HIGH SENSITIVITY C-REACTIVE PROTEIN AS A MARKER FOR 
DIASTOLIC DYSFUNCTION IN PATIENTS WITH CARDIOVASCULAR 
RISK FACTORS 
 
Name:   Age:   Sex: 
 
Address:    Occupation: 
 
Symptoms: 
 Dyspnea                                       
 Orthopnea\PND 
 Syncope\palpitation 
 Chest pain 
 Oliguria 
 Abdominal distension 
 Swelling of legs 
 Puffiness of Face 
 Fever 
 
 
Past history: 
 Diabetes mellitus  
 Hypertension 
 Dyslipidemia 
 Coronary artery disease/CVA/RHD 
 Other co morbid illnesses 
 
 
Personal history:Smoking, Alcoholism 
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General examination: 
Anthropometry:       Height(in cm): Weight(in kg): 
PULSE:             BLOOD PRESSURE: 
GENERAL EXAMINATION: 
SYSTEMIC EXAMINATION: 
CVS:                   RS:  
ABDOMEN:                 CNS: 
INVESTIGATIONS: 
Hb:                           TC:                      DC:                                 ESR:  
Blood Glucose(Fasting) : 
Blood Urea : 
Serum Creatinine : 
Total Cholesterol : HDL : 
Triglycerides : LDL : 
Hs-CRP                        : 
 
ECG: 
 
ECHO CARDIOGRAM: 
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PATIENT CONSENT FORM 
Study Detail : ―HIGH SENSITIVITY C-REACTIVE PROTEIN 
AS A MARKER FOR DIASTOLIC 
DYSFUNCTION IN PATIENTS WITH 
CARDIOVASCULAR RISK FACTORS‖ 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction.                                                                                       
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected.    
 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study.        
I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms.                                                                  
I hereby consent to participate in this study.                                                          
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological, biochemical, radiological tests.                                         
 
 
Signature/thumb impression                                 
Patient’s Name and Address: 
 
Signature of Investigator 
Study Investigator’s 
Name:Dr.V.C.Poornachandran. 
 95 
 
MASTER CHART 
S.NO. NAME AGE SEX OP NO. BMI HT DM DL GROUP EF% DD hsCRP 
1 Aysha beevi 52 F 2150 31.2 y N N A 61 Gr-I 0.67 
2 Rathnammal 51 F 5213 30.6 Y Y N C 58 Gr-I 0.78 
3 Dhanasekaran 60 M 4450 30.6 Y N N A 62 Gr-I 0.59 
4 Srinivasan 60 M 1886 32.9 Y Y N C 57 Gr-II 1.67 
5 Radhakrishnan 56 M 3573 31.5 Y Y N C 61 Gr-II 1.97 
6 Kuppusamy 60 M 2412 32.5 y N N A 59 Gr-I 0.74 
7 Marimuthu 50 M 1888 27.9 Y Y N C 63 NIL 0.32 
8 Murugan 30 M 3226 24.2 Y N N A 64 NIL 0.19 
9 Senthamarai 68 M 3539 32.7 Y N N A 56 Gr-II 1.04 
10 Meena 45 F 5588 29.8 Y N Y D 58 Gr-I 0.64 
11 Perumal 60 M 3478 28.4 Y N N A 62 Gr-I 0.73 
12 Subramani 57 M 1851 33.4 Y N N A 63 Gr-I 0.81 
13 Ramamurthy 70 M 1514 30.5 Y N N A 58 Gr-II 1.62 
14 Murugesan 58 M 2197 33.5 Y Y Y G 56 Gr-II 2.25 
15 MeharTaj 39 F 3696 23.4 Y N N A 62 NIL 0.24 
16 Anwar basha 70 M 4731 34.7 Y Y N C 56 Gr-II 2.17 
17 Munipandi 65 M 1311 28.4 Y Y N C 59 Gr-II 1.97 
18 Padma 52 F 5581 34.8 Y Y N C 57 NIL 0.48 
19 Munikrishnan 57 M 1594 36.2 Y N N A 62 Gr-I 0.83 
20 Aravalli 53 F 1571 32.5 Y Y N C 54 NIL 0.25 
21 Jagadesswari 55 F 1661 28.4 Y N N A 58 Gr-I 0.73 
22 Rani 57 F 1750 32.5 Y N N A 61 Gr-I 0.61 
23 Gangammal 58 F 2735 30.5 Y N N A 54 Gr-I 0.58 
24 Hussain beevi 60 F 2522 32.5 Y N N A 56 Gr-II 1.37 
25 Jothi 58 F 4697 33.5 Y N N A 60 Gr-I 0.91 
26 Baskar 58 M 2742 33.9 Y Y N C 57 Gr-II 2.05 
27 Mohanraj 56 M 4316 29.4 Y N N A 62 NIL 0.34 
28 Savitha 45 F 1873 27.4 Y N N A 63 NIL 0.41 
29 Kannagi 42 F 1691 26.4 Y N N A 61 NIL 0.27 
30 Selvakumari 60 F 1885 33.4 Y Y N C 55 Gr-I 0.86 
31 Paappammal 75 F 1420 29.4 Y Y N C 59 Gr-I 0.92 
32 Usha rani 45 F 1105 26.4 Y N N A 64 NIL 0.14 
33 Kanthammal 57 F 2584 28.4 Y N Y D 62 Gr-I 0.54 
34 Padmavathy 47 F 6472 32.5 N Y N B 61 Gr-I 0.61 
35 Thenmozhi 38 F 4066 24.6 N Y N B 63 NIL 0.39 
36 Gandhi 51 M 7381 34.5 Y  Y N C 64 NIL 0.31 
37 Narayanan 53 M 1959 32.4 N Y N B 66 Gr-I 0.76 
38 Subramani 55 M 2971 31 Y Y N C 58 NIL 0.18 
39 Venkaiya 64 M 5788 29.4 Y  Y N C 56 Gr-I 0.74 
40 Jayalakshmi 69 F 3578 35.4 N Y N B 64 Gr-II 1.34 
41 Pavunammal 65 F 3477 28.4 N Y N B 61 Gr-II 0.96 
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S.NO. NAME AGE SEX OP NO. BMI HT DM DL GROUP EF% DD hsCRP 
42 Malliga 58 F 1768 33.7 Y y N C 58 Gr-I 0.63 
43 Muthulaksmi 45 F 4129 34.8 N Y N B 64 Gr-I 1.12 
44 Viola mary 55 F 3659 28.4 N Y N B 65 Gr-I 0.83 
45 Venkatesh 40 M 1223 27.4 N Y N B 68 Gr-I 0.76 
46 Arumugam 55 M 4449 33.4 Y Y N C 62 Gr-I 0.84 
47 Kannadas 48 M 4456 26.7 Y Y N C 64 NIL 0.74 
48 Parimala 66 F 3560 36.4 Y Y Y G 61 Gr-II 2.54 
49 Sarada 65 F 2262 35.7 N Y N B 66 Gr-I 0.71 
50 Selvaraj 52 M 3409 33.7 N Y N B 67 Gr-II 1.31 
51 Raji 42 M 4511 24.5 N Y N B 65 NIL 0.27 
52 Manickam 45 M 4803 26.4 N Y N B 66 Gr-I 0.61 
53 Balan 61 M 5174 34.5 Y Y N C 61 NIL 0.17 
54 Manonmani 75 F 2165 32.7 Y Y Y G 58 Gr-II 2.55 
55 Kathiravan 40 M 5261 28.4 N Y N B 67 NIL 0.48 
56 Vasanthan 60 M 2524 35.7 Y Y N C 64 Gr-II 1.65 
57 Rajendran 49 M 4382 29.4 y y N C 60 Gr-I 1.24 
58 Ansari Ahmed 65 M 3068 35.8 Y Y Y G 61 Gr-II 1.85 
59 Chandra 62 F 7467 34.7 Y N Y D 62 Gr-II 1.62 
60 Ganesan 41 M 2910 28.2 N Y N B 63 NIL 0.17 
61 Tamilselvi 44 F 1769 32 Y N Y D 64 NIL 0.48 
62 Amudha 38 F 1356 24.2 N Y N B 62 NIL 0.31 
63 Ramesh 36 M 5014 23.8 N Y N B 66 NIL 0.21 
64 Kamala 61 F 8024 33.6 Y Y Y G 59 Gr-I 2.14 
65 Saroja 49 F 3548 31.2 N Y Y E 60 NIL 0.36 
66 Ayyappan 39 M 1982 26.2 Y N Y D 68 NIL 0.21 
67 Dhandapani 55 M 4687 30.5 Y Y Y G 57 Gr-I 1.95 
68 Chandrasekar 41 M 3121 27.6 N Y Y E 63 NIL 0.24 
69 Ganga 45 F 8420 29.4 N Y Y E 59 NIL 0.41 
70 leelavathy 42 F 4306 31.4 Y N Y D 60 NIL 0.39 
71 Arasu 52 M 1274 32.7 Y Y Y G 58 Gr-I 0.85 
72 Rajalaksmi 59 F 2145 33.7 N Y Y E 56 Gr-II 1.24 
73 Krishnaveni 56 F 3015 30.6 Y Y N C 59 Gr-I 0.82 
74 Ravi kumar 50 M 2187 29.4 N Y Y E 61 NIL 0.26 
75 Jothimani 62 M 5014 33.7 Y Y Y G 57 Gr-II 1.76 
76 kalaiselvi 33 F 1031 26.7 N Y Y E 64 NIL 0.31 
77 Indra 39 F 2597 27.3 Y N Y D 66 NIL 0.41 
78 Shamshad 48 M 8245 29.4 Y Y N C 61 NIL 0.24 
79 soundarajan 45 M 6017 28.2 N Y N B 62 Gr-I 0.72 
80 Kuppan 42 M 3587 27.3 Y N Y D 65 NIL 0.28 
81 Ahmed basha 50 M 1305 32.7 Y Y Y G 59 NIL 0.47 
82 lewis  47 M 5124 26.8 N Y Y E 63 NIL 0.41 
83 Akbar Ali 55 M 5385 32.5 Y Y Y G 58 Gr-I 1.25 
84 Dhanalakshmi 50 F 6501 31.3 N Y Y E 59 Gr-I 0.95 
85 Munusamy 51 M 8055 30.8 Y Y Y G 56 NIL 0.26 
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S.NO. NAME AGE SEX OP NO. BMI HT DM DL GROUP EF% DD hsCRP 
86 Anbu 45 M 4782 29.4 Y N Y D 64 Gr-I 0.69 
87 Jaya kumar 58 M 6612 32.4 Y Y Y G 56 Gr-II 2.36 
88 Lakshmi devi 52 F 1236 30.5 N Y Y E 58 Gr-I 0.81 
89 Kannaiah  58 M 3025 31.6 Y Y Y G 56 Gr-I 1.68 
90 Mohanraj 42 M 1789 24.7 Y N N A 62 NIL 0.39 
91 Jamuna  50 F 1857 29.3 Y N Y D 59 Gr-I 0.71 
92 Siva kumar 40 M 6125 28.6 N Y N B 66 Gr-I 0.83 
93 Baskar 49 M 5241 32.8 N Y Y E 61 NIL 0.36 
94 Shanthi kala 64 F 4589 34.2 Y Y Y G 56 Gr-II 2.23 
95 Rose mary 45 F 7541 29.5 N Y Y E 60 NIL 0.23 
96 Muthpandi 52 M 3698 31.6 N Y Y E 59 Gr-I 0.95 
97 Praskash 36 M 4658 28.5 N Y N B 68 NIL 0.19 
98 Lalitha 46 F 1087 29.4 N Y Y E 61 NIL 0.26 
99 Muthusamy 54 M 5713 27.4 N Y Y E 59 Gr-I 0.79 
100 Balaji 48 M 6278 26.3 N Y N B 60 Gr-I 0.73 
 
KEY TO MASTER CHART 
BMI- BODY MASS INDEX 
HT- HYPERTENSION 
DM- DIABETES MELLITUS 
DL- DYSLIPIDEMIA 
EF-EJECTION FRACTION 
DD- DIASTOLIC DYSFUNCTION 
 
 
 
